“TnBC patients ALL have zero CTC – this is in contrast to earlier statements that used the word “most” patients (this one is for CDiddy).”

Cancer is why I’m here and why I loaded the boat last year in the .30-40 range. I increased my holdings by 10x because of the preclinical and initial patient data. I still believe that leronlimab will be a blockbuster cancer drug and will make billions of dollars annually, if not tens of billions, once its approved for mTNBC and other metastatic cancers.

I’d like to hear about the pre-BTD meeting for mTNBC or enrollment #s for the cancer trials.